Vaxxas adds three expert advisors to provide regulatory and manufacturing advice

Clinical stage biotechnology company Vaxxas, which is commercialising a needle-free vaccine delivery platform, has added three new expert advisors to its product development and strategy team.

In a statement on Thursday morning (Australian time), the company said Dr Emilio Emini, Dr Nathalie Garcon, and Professor Paul Young will join Vaxxas as consultants to provide regulatory and manufacturing advice to Chief Medical Officer Dr Rochelle Chaiken and Chief Technology Officer Dr Angus Forster.

The advisors are located in the United States, Europe and Australia.

Vaxxas is advancing its high-density microarray patch (HD-MAP) vaccine delivery method towards later-stage clinical trials and commercialisation. HD-MAP is being used in trials to deliver vaccines including for Covid-19, influenza and typhoid, with applicator patches being made at a factory in Brisbane.

CEO David Hoey said, “Expanding our international product development expertise is a strategic priority for Vaxxas as we advance our technology towards later-stage clinical trials, large-scale manufacturing, and eventual commercialisation.

“Our needle-free technology has the potential to transform the way life-saving vaccines are delivered globally, so it is critical to have this international representation and input.”

Vaxxas was established in 2011 to commercialise MAPs for vaccine delivery, based on research at University of Queensland.

Picture: supplied

Further reading

Vaxxas awarded $5.4 million for typhoid vaccine clinical studies

Vaxxas opens new Brisbane manufacturing facility

Vaxxas licenses RSV vaccine candidate

Clinical trials begin for flu vaccine-coated Vaxxas patches

Gradually getting under your skin